Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acted for Carnegie and Kempen & Co in connection with BioInvent’s private placement of new shares
Mandate

Vinge acted for Carnegie and Kempen & Co in connection with BioInvent’s private placement of new shares

June 09, 2011

BioInvent International AB (publ) (NASDAQ OMX Stockholm) has completed a private placement of new shares with international institutional investors and qualified investors in Sweden through an accelerated bookbuilding procedure. Carnegie Investment Bank and Kempen & Co acted as Joint Global Co-ordinators and Joint Bookrunners.

Vinge and Latham & Watkins were legal advisors to the bookrunners. The Vinge team was headed by capital markets partner Erik Sjöman.

Related

Vinge advises HealthCap in conjunction with an investment in Neobiomics

 HealthCap is investing in Neobiomics AB, which develops products in the neonatal field. Neobiomics’ flagship product, Proprems, is a probiotic dietary supplement developed for preterm infants.
May 22, 2026

Vinge advises Sveafastigheter in its merger with KlaraBo

 Vinge advises Sveafastigheter AB (publ) in its merger with KlaraBo Sverige AB.
May 22, 2026

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

 Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026